| 2019-03-19 05:16:03|
RHHBY 05:16 03/19 03/19/19
Roche announces FDA approval of Tecentriq with chemotherapy for lung cancer
Roche announced that the FDA approved Tecentriq, in combination with chemotherapy, for the initial treatment of adults with extensive-stage small cell lung cancer. "Tecentriq is the first cancer immunotherapy approved for the initial treatment of extensive-stage small cell lung cancer, which is especially difficult to treat," said Sandra Horning, M.D., Roche's Chief Medical Officer and Head of Global Product Development. "Until now, there have been limited treatment advances for this disease, and we are excited to bring a potential new standard of care to patients that has been shown to improve survival compared to chemotherapy."